Pharmaceuticals News and Research

RSS

LCT successfully implants first patient with potential Parkinson's disease treatment

Living Cell Technologies Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL – a potential treatment for Parkinson's disease.

20 Sep 2013

Orbeshield Earns Soligenix Up To $26.3M From BARDA

...

19 Sep 2013

BARDA Exercises $6M Option For Aeolus' Acute Radiation Syndrome Drug

...

19 Sep 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.

19 Sep 2013

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Ventana Medical Systems, Inc., a member of the Roche Group, and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

19 Sep 2013

Overactivity of EGFR protein leads to heightened cancer growth and chemotherapy resistance

Overactivity of a protein that normally cues cells to divide sabotages the body-s natural cellular recycling process, leading to heightened cancer growth and chemotherapy resistance, UT Southwestern Medical Center researchers have found.

19 Sep 2013

Life science products from AXT to be exhibited at ComBio 2013

AXT, Australia’s leading supplier of analytical and sample preparation equipment will be exhibiting at the ComBio 2013 conference from September 29 to October 3, at the Perth Convention and Exhibition Centre, Western Australia, organised by the Australian Society for Biochemistry and Molecular Biology.

18 Sep 2013

New series of lectures focus on rodents, medicines and drug developments

Rodents, medicines and drug developments are all on the agenda during a new series of public lectures being staged by the University of Greenwich's Faculty of Engineering & Science.

18 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

GenesisSolutions hosts Life Sciences EAM Symposium

GenesisSolutions, a Fully Integrated Global EAM Service Provider will be hosting a complimentary Life Sciences EAM Symposium for Engineering, Maintenance & Reliability professionals on Tuesday, November 5, 2013 at The Umstead Hotel in Cary, North Carolina.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

PCI announces innovative developments in its anti counterfeiting initiatives for pharmaceutical packaging

Packaging Coordinators, Inc. (PCI), a global supplier of pharmaceutical commercial packaging solutions and clinical trials services today announces innovative developments in its anti counterfeiting initiatives for pharmaceutical packaging. The company’s new service offering is outlined in a new white paper that is available to download via PCI anti-counterfeiting white paper and details its innovative identification solution, which uses a unique identification code on each pack, generated and applied by the packer.

From Packaging Coordinators Inc. (PCI) 17 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

Researchers develop new variety of corked microbottle for drugs

Sustained-release formulations that release drugs over longer periods of time are not the final step in the evolution of “intelligent” drug delivery systems. Modern pharmaceuticals are being designed to be released only in a specific, diseased organ; on cues from our circadian rhythm; or under specific physiological conditions.

17 Sep 2013

Researchers identify potentially treatable subtype of pancreatic cancer

Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.

17 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

Pharmaceuticals News and Research

LCT successfully implants first patient with potential Parkinson's disease treatment

Orbeshield Earns Soligenix Up To $26.3M From BARDA

BARDA Exercises $6M Option For Aeolus' Acute Radiation Syndrome Drug

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Overactivity of EGFR protein leads to heightened cancer growth and chemotherapy resistance

Life science products from AXT to be exhibited at ComBio 2013

New series of lectures focus on rodents, medicines and drug developments

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GenesisSolutions hosts Life Sciences EAM Symposium

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

PCI announces innovative developments in its anti counterfeiting initiatives for pharmaceutical packaging

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Researchers develop new variety of corked microbottle for drugs

Researchers identify potentially treatable subtype of pancreatic cancer

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence